Browsing by author "Bruna Cabot, Alejandra"
Now showing items 1-16 of 16
-
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.
Bruna, A; Rueda, OM; Greenwood, W; Batra, AS; Callari, M; et al. (CELL PRESS, 2016-09-22)The inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured in pre-clinical models. We have created a large collection of breast cancer patient-derived tumor xenografts (PDTXs), in which the ... -
ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.
Nagarajan, S; Rao, SV; Sutton, J; Cheeseman, D; Dunn, S; et al. (NATURE PORTFOLIO, 2020-02-01)Using genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screens to understand endocrine drug resistance, we discovered ARID1A and other SWI/SNF complex components as the factors most critically ... -
BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
Tacconi, EM; Lai, X; Folio, C; Porru, M; Zonderland, G; et al. (WILEY, 2017-10-01)Maintenance of genome integrity requires the functional interplay between Fanconi anemia (FA) and homologous recombination (HR) repair pathways. Endogenous acetaldehyde, a product of cellular metabolism, is a potent source ... -
Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
Tacconi, EM; Badie, S; De Gregoriis, G; Reisländer, T; Lai, X; et al. (WILEY, 2019-07-01)Due to compromised homologous recombination (HR) repair, BRCA1- and BRCA2-mutated tumours accumulate DNA damage and genomic rearrangements conducive of tumour progression. To identify drugs that target specifically ... -
Deciphering the signaling network of breast cancer improves drug sensitivity prediction.
Tognetti, M; Gabor, A; Yang, M; Cappelletti, V; Windhager, J; et al. (CELL PRESS, 2021-05-19)One goal of precision medicine is to tailor effective treatments to patients' specific molecular markers of disease. Here, we used mass cytometry to characterize the single-cell signaling landscapes of 62 breast cancer ... -
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Gris-Oliver, A; Palafox, M; Monserrat, L; Brasó-Maristany, F; Òdena, A; et al. (AMER ASSOC CANCER RESEARCH, 2020-07-15)PURPOSE: AZD5363/capivasertib is a pan-AKT catalytic inhibitor with promising activity in combination with paclitaxel in triple-negative metastatic breast cancer harboring PI3K/AKT-pathway alterations and in estrogen ... -
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Palafox, M; Monserrat, L; Bellet, M; Villacampa, G; Gonzalez-Perez, A; et al. (NATURE PORTFOLIO, 2022-09-07)CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are ... -
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Serra, V; Wang, AT; Castroviejo-Bermejo, M; Polanska, UM; Palafox, M; et al. (AMER ASSOC CANCER RESEARCH, 2022-10-14)PURPOSE: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance ... -
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response.
Georgopoulou, D; Callari, M; Rueda, OM; Shea, A; Martin, A; et al. (NATURE PORTFOLIO, 2021-03-31)The heterogeneity of breast cancer plays a major role in drug response and resistance and has been extensively characterized at the genomic level. Here, a single-cell breast cancer mass cytometry (BCMC) panel is optimized ... -
Metabolic imaging with hyperpolarized [1-13C] pyruvate in patient-derived preclinical mouse models of breast cancer.
Ros, S; Wright, AJ; Bruna, A; Caldas, C; Brindle, KM (ELSEVIER, 2021-09-17)13C nuclear spin hyperpolarization can increase the sensitivity of detection in an MRI experiment by more than 10,000-fold. 13C magnetic resonance spectroscopic imaging (MRSI) of hyperpolarized 13C label exchange between ... -
Patient-derived tumour xenografts for breast cancer drug discovery.
Cassidy, JW; Batra, AS; Greenwood, W; Bruna, A (BIOSCIENTIFICA LTD, 2016-12-01)Despite remarkable advances in our understanding of the drivers of human malignancies, new targeted therapies often fail to show sufficient efficacy in clinical trials. Indeed, the cost of bringing a new agent to market ... -
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Castroviejo-Bermejo, M; Cruz, C; Llop-Guevara, A; Gutiérrez-Enríquez, S; Ducy, M; et al. (WILEY, 2018-12-01)Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) are effective in cancers with defective homologous recombination DNA repair (HRR), including BRCA1/2-related cancers. A test to identify additional HRR-deficient tumors ... -
RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.
Ciscar, M; Trinidad, EM; Perez-Chacon, G; Alsaleem, M; Jimenez, M; et al. (WILEY, 2023-04-11)Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed ... -
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Dev, H; Chiang, T-WW; Lescale, C; de Krijger, I; Martin, AG; et al. (NATURE PUBLISHING GROUP, 2018-08-01)BRCA1 deficiencies cause breast, ovarian, prostate and other cancers, and render tumours hypersensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. To understand the resistance mechanisms, we conducted whole-genome ... -
The Promise of Patient-Derived Preclinical Models to Accelerate the Implementation of Personalised Medicine for Children with Neuroblastoma.
Tucker, ER; George, S; Angelini, P; Bruna, A; Chesler, L (MDPI, 2021-03-30)Patient-derived preclinical models are now a core component of cancer research and have the ability to drastically improve the predictive power of preclinical therapeutic studies. However, their development and maintenance ... -
Vitamin B5 supports MYC oncogenic metabolism and tumor progression in breast cancer.
Kreuzaler, P; Inglese, P; Ghanate, A; Gjelaj, E; Wu, V; et al. (NATURE PORTFOLIO, 2023-11-01)Tumors are intrinsically heterogeneous and it is well established that this directs their evolution, hinders their classification and frustrates therapy1-3. Consequently, spatially resolved omics-level analyses are gaining ...